Amylyx Pharmaceuticals Inc. (NASDAQ: AMLX) said on Wednesday it priced a public offering of 14.09 million shares of common stock at $35.50 per share, generating gross proceeds of approximately $500.2 million.
The offering, subject to customary closing conditions, is expected to close on or about Friday, August 22. Underwriters Leerink Partners, Morgan Stanley, Guggenheim Securities, and LifeSci Capital have a 30-day option to purchase up to an additional 2.11 million shares at the same price, subject to underwriting discounts and commissions.
Net proceeds, after deducting underwriting discounts and expenses, will support pre-commercial activities for avexitide, including securing additional manufacturing capacity, research and development, and general corporate purposes. Amylyx develops investigational therapies for endocrine and neurodegenerative diseases.
The shares are being offered under a shelf registration statement on Form S-3ASR, which became automatically effective upon filing with the U.S. Securities and Exchange Commission on March 3, 2026. The company filed the preliminary prospectus supplement and final prospectus with the SEC on Monday.
